Skip to main content
. 2013 Mar 6;34(22):1670–1680. doi: 10.1093/eurheartj/eht049

Figure 4.

Figure 4

Effect of adding an oral anticoagulant to single (aspirin) or dual (aspirin and clopidogrel) antiplatelet therapy on rates of major adverse cardiovascular events (A) and TIMI major bleeding events (B) after an acute coronary syndrome in a subgroup of phase III studies. Effect estimates of individual study arms with horizontal lines representing 95% CI; coloured diamonds, subtotal effects, and 95% CI from random effects models for direct thrombin inhibitors and factor Xa inhibitors, respectively, and overall effects in addition to single and dual antiplatelet therapy; open diamonds, subtotal summary effects, and 95% CI from random effects models per trial; HR, hazard ratio; CI, confidence interval; ARR, absolute risk reduction (risk difference); b.i.d., twice daily; o.d., once daily; MACE, major adverse cardiovascular events, i.e. a composite of all-cause mortality, myocardial infarction and stroke.